Brokerage Reports
Genmab A/S Sponsored ADR [GMAB]
Reports for Purchase
Showing records 81 - 100 ( 114 total )
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Tisotumab Phase 2 Results Appear In Line With Prior Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 10.00
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
ANDROMEDA Establishes New Key AL Amyloidosis Regimen; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 10.00
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Initial Takeaways From EHA 2020; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 25.00
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
AbbVie Partnership Cements Genmab''s Long-Term Strategy; Raising PT to $40
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 25.00
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Subcutaneous Daratumumab Form Wins European Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 10.00
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
ARZERRA Delay and Sarclisa European Approval Non-Impactful, in Our View; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 10.00
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
ANDROMEDA Results Scintillate; Key ASCO Takeaways; Raising PT to $34
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 25.00
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Epcoritamab Impresses in ASCO Abstract; Other ASCO Pipeline Insights; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 25.00
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Subcutaneous DARZALEX Receives FDA Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 25.00
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Positive European Opinion on Subcutaneous DARZALEX; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 25.00
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Subcutaneous Daratumumab Formulation Filed in Japan; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 10.00
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Revising Near-Term DARZALEX Forecasts; Reiterate Buy; Modulating PT to $28
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 10.00
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Regional Deal Involving Competing Bispecific Bodes Well for Epcoritamab; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 10.00
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
DARZALEX Franchise Seems Relatively Immune to COVID-19; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 10.00
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Market Shudders But We See Names to Outperform.
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Price: 150.00
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
JNJ-61186372 Receives Breakthrough Designation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 10.00
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Empliciti Failure in Front-Line Multiple Myeloma Removes DARZALEX Threat; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 10.00
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
DARZALEX Competitor Approval Non-Impactful, in Our View; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 10.00
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Pipeline Focus in 2020; 2019 Financials; Reiterate Buy; Raising PT to $29
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 50.00
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Another DARZALEX Regimen Regulatory Filing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 10.00